Your SlideShare is downloading. ×
Cystic pancreatic lesions
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Cystic pancreatic lesions


Published on

Published in: Health & Medicine

  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Imaging of Pancreatic Cystic Lesions John Murray MD, Bruce Stewart MD & Alvin Yamamoto MD NSMC Radiology Department Meeting February 4, 2009
  • 2. Outline1. BS: Overview & Approach to Cystic Pancreatic Lesions2. JM: Intraductal Papillary Mucinous Neoplasms (IPMN)3. AY: NSMC Cases
  • 3. Introduction Increasingly incidentally detected  More than 1/3 asymptomatic Imaging important for determining prognosis and management CT>MR generally preferred for characterization except for IPMN Simple classification for approach to DDx  DDx discussed here account for 90% lesions Role of Endoscopic US
  • 4. Cystic Pancreatic lesions: A SimpleImaging-based Classification System for Guiding Management Sahani DV, Kadavigere R, Saokar A, Fernandez-del Castillo C, Brugge WR, Hahn PF. Radiographics 2005 Nov-Dec;25(6):1471-84.
  • 5. Classification of Cystic Pancreatic Lesions Pseudocyst Common cystic pancreatic neoplasms  Serous cystadenoma  Mucinous cystic neoplasm  IPMN Rare cystic pancreatic neoplasms  Solid pseudopapillary tumor  Acinar cell cystadenocarcinoma  Lymphangioma  Hemangioma  Paraganglioma
  • 6. Classification of Cystic Pancreatic Lesions (cont) Solid pancreatic lesions with cystic degeneration  Pancreatic adenocarcinoma  Cystic islet cell tumor (insulinoma, glucagonoma, gastrinoma)  Metastasis  Cystic teratoma  Sarcoma True epithelial cysts* *Associated with von Hippel–Lindau disease, autosomal -dominant polycystic kidney disease, and cystic fibrosis)
  • 7. Four Morphologic Types of Cystic Lesions of the Pancreas
  • 8. Unilocular Cyst Pseudocyst IPMN occasionally Unilocular serous cystadenoma Lymphoepithelial cyst Multiple  von Hippel-Lindau  Pseudocysts
  • 9. Pseudocyst Generally symptomatic (i.e. pain)  If asymptomatic, think about another Dx History of acute or chronic pancreatitis  Almost always pseudocyst with this history Look for associated findings  Pancreatic inflammation, parenchymal calcifications, atrophy, typical intraductal calcifications Can communicate with pancreatic duct  Wide neck vs. narrow neck for IPMN Wall can calcify No mural nodules
  • 10. Pseudocyst
  • 11. Pseudocyst in a patient with a recent history of pancreatitis
  • 12. Side-branch IPMN manifesting as a unilocular cyst
  • 13. Multiple unilocular cysts in a patient with von Hippel–Lindau disease
  • 14. Microcystic Lesions Serous cystadenoma  Only lesion included in this category Benign tumor “Grandmother Lesion” May grow up to approx 4 mm/year 70% cases demonstrate:  Polycystic/microcystic pattern  Collection of cysts (>6)  Range: few mm – 2 cm  External lobulations  Enhancing septa, walls 30% demonstrate fibrous central scar +/- stellate calcifcation Other variants (macrocystic + oligocystic)
  • 15. Serous cystadenoma in 2 patients
  • 16. Serous cystadenoma(macrocystic variant)
  • 17. Macrocystic Lesions Mucinous cystic neoplasms Intraductal Papillary Mucinous Neoplasm (IPMN)
  • 18. Mucinous cystic neoplasms Mucinous cystadenomas & cystadenocarcinomas Multilocular with complex internal architecture  May contain internal hemorrhage or debris  Peripheral eggshell Ca++ predictive of malignancy  Body & tail of pancreas Asymptomatic in 75% cases  If symptoms, usually due to mass effect “Mother Lesion” High potential for malignancy Surgical resection yields good prognosis
  • 19. Mucinous cystadenomamanifesting as a multiseptated cyst
  • 20. Mucinous cystadenocarcinoma
  • 21. Mucinous cystic tumor
  • 22. Mucinous cystadenoma
  • 23. IPMNPathology: Borderline IPMN w/o in situ or invasive carcinoma Radiographics 2005; 25:1451-1470
  • 24. Endoscopic US Can provide detailed morphologic evaluation of cystic lesions  For detecting malignant tumors:  Sensitivity: 40%  Specificity: 100%  Accuracy: 50% Advantage of aspiration of contents, sampling of cyst wall, septa or mural nodule  Less potential for tumor seeding than percutaneous sampling  Highly viscous contents (mucin) consistent with mucinous neoplasm  Tumor markers, cytologic analysis, biochemical markers, fluid amylase At NSMC, performed by Drs. Jeff Oringer & Khoa Do
  • 25. Cysts with a solid component Unilocular or multilocular True cystic tumors or solid pancreatic neoplasms with cystic component/degeneration Wide DDx  Mucinous cystic neoplasms  IPMNs  Islet cell tumor  Solid pseudopapillary tumor (SPEN)  Adenocarcinoma  Metastasis All malignant or have a high malignant potential Surgical management
  • 26. Islet cell tumor manifesting as a cyst with a solid component
  • 27. Solid pseudopapillary tumormanifesting as a cyst with a solid component
  • 28. Metastases manifesting as cysts with solid components Pancreatic Adenocarcinoma Malignant IPMN
  • 29. Management
  • 30. Follow-up No consensus 6 month intervals for 1st year Annual imaging for 3 years
  • 31. Pearls  Age & Gender  “Daughter Lesion”: SPEN  “Mother Lesion”: Mucinous cystic  “Grandmother Lesion”: Serous cystadenoma  Location  Head/neck for serous & side branch IMPN  Body/tail for mucinous cystic neoplasm  Calcification  Peripheral in mucinous cystic  Central in serous cystadenoma  Mural Nodularity (enhancement = neoplasm)  Duct communication (narrow neck) favors IPMNFrom Stat Dx: Cystic Pancreatic Mass & Seminars in US, CT & MRI 2007; 28: 3389-356